Physician profile
David B Willingham
NPI 1467441642
$4,888.46
in general payments reported to CMS, 2019-2025
28 companies · $331 in 2025
The $331 reported for 2025 was more than what a typical Adult Medicine provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $815 · 2020: $583 · 2021: $1,300 · 2022: $901 · 2023: $435 · 2024: $523 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,288.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,024.73 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $887.18 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $395.95 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $315.03 | 2019-2022 | |
| Abbvie INC. | $306.65 | 2021-2024 | Vraylar, Ubrelvy |
| Amgen INC. | $283.66 | 2019-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.25 | 2019-2022 | |
| Astellas Pharma US INC | $171.02 | 2021-2024 | Veozah |
| Glaxosmithkline, LLC. | $169.24 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $149.34 | 2021-2024 | Freestyle Libre 3 |
| Pfizer INC. | $138.21 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $123.33 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $106.55 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $93.35 | 2020-2021 | |
| Eisai INC. | $90.08 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $80.06 | 2019-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $66.97 | 2020-2024 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $51.86 | 2022 | |
| Allergan, INC. | $43.71 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.72 | 2022-2025 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $24.16 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.15 | 2025 | Xifaxan |
| Exact Sciences Corporation | $16.63 | 2024 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $14.89 | 2023 | Auvelity |
| Zyla Life Sciences, INC. | $14.75 | 2020 | |
| Tactile Systems Technology INC | $14.04 | 2019 | |
| International Rehabilitative Sciences, INC | $13.66 | 2024 | Rs 4i Plus Sequential Stimulator |
| Arbor Pharmaceuticals, INC. | $12.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Willingham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.